Kirkland & Ellis counseled RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, in connection with its agreement to be acquired by Telix Pharmaceuticals Limited (ASX: TLX), a biopharmaceutical company listed on the Australian Securities Exchange. The acquisition is currently expected to close early in the first quarter of 2025, subject to obtaining regulatory approvals and satisfaction of other customary closing conditions.

The Kirkland team was led by corporate partners Jonathan Davis and Joseph Casey and associates Zahraa Hadi and Connor O’Flaherty; tax partners Sara Zablotney and Mike Conroy; energy regulatory partner Drew Stuyvenberg; healthcare partner Anthony Del Rio and associates Micah Desaire and Giselle Lai; executive compensation partner Stephen Brecher; and employee benefits partner Jeffrey Quinn.